Design Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Design Therapeutics

09/05/2023 23:14

* Design Therapeutics Inc  DSGN.OQ  reported a quarterly
adjusted
loss of 35 cents​​ per share for the quarter ended in March. The
mean expectation of five analysts for the quarter was for a loss
of 36 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Design Therapeutics Inc's reported EPS for the quarter was
a
loss of 35 cents​.
    * The mean earnings estimate of analysts had risen by
about 2.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Design Therapeutics Inc shares had risen by 31.7% this
quarter and lost 25.9% so far this year.
    * The company reported a quarterly loss of $19.29 million.
    * Wall Street's median 12-month price target for Design
Therapeutics Inc is $22.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
9 at 10:14 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.36          -0.35          Beat
 Dec. 31 2022      -0.34          -0.31          Beat
 Sep. 30 2022      -0.29          -0.32          Missed
 Jun. 30 2022      -0.25          -0.27          Missed